IMITREX was created by Glaxo Wellcome specifically to treat
migraines. Some medications may just dull pain. IMITREX is believed to target the nerves
and blood vessels that can trigger the throbbing pain, nausea, and sensitivity to light
and sound. Of course, IMITREX works anytime during a migraine. But when taken at the
beginning of a migraine attack, it may be more effective without causing drowsiness.
And since IMITREX is not an addictive narcotic or barbiturate, your migraine pain can be
relieved while you remain active, alert, and in control.
Only your Doctor can decide if IMITREX is right for you.
IMITREX is for the acute treatment of migraine attacks, with or without aura, in adults.
You should not take IMITREX if you have certain types of
heart disease, a history of stroke or transient ischemic attacks, peripheral vascular
disease, Raynaud’s syndrome, blood pressure that is uncontrolled, or are allergic to
this medication. If you have risk factors for heart disease, such as high blood pressure,
high cholesterol, diabetes, or are a smoker, you should be evaluated by your doctor before
taking IMITREX. Very rarely, certain people, even some without heart disease, have had
serious heart-related problems when taking IMITREX.
If you are currently taking other medications, particularly MAO inhibitors and
ergotamines, or other migraine medications, or if you are pregnant, nursing, or thinking
about becoming pregnant, you should talk to your doctor. If the headaches you are
suffering from are not migraines, IMITREX is not for you.
Imitrex should only be used where a clear diagnosis of migraine has been established. It is not intended for the prophylactic therapy of migraine or for use in the management of basilar or hemiplegic migraine.
SAN FRANCISCO, CA -- June 26, 1998 -- Glaxo Wellcome
Inc.’s Imitrex(R) (sumatriptan) (sumatriptan succinate) provides fast and
consistently effective relief of migraine, according to data being presented this week at
the 40th annual meeting of the American Association for the Study of Headache (AASH).
It has been used to treat more than 160 million migraine attacks in eight million patients
world-wide.
